05 September 2024
05 September 2024
ProKidney is prioritising one of two clinical studies evaluating rilparencel, to bring the cell therapy to the US market quicker.
The Phase II/III fosgonimeton study was started after efficacy signals were noted in a subgroup analysis from an earlier Phase II trial.
Pfizer Ignite will support Acepodia in developing its pipeline cancer therapeutic candidates.
The move to classify xylazine as a Class C drug follows the Advisory Council on the Misuse of Drugs’ recommendation.
Actimed says S-oxprenolol shares a similar pharmacology to its lead product S-pindolol, which is being studied in cachexia.
In clinical trials, 95% of patients who received the treatment experienced no tumour growth over two years.
EVA Pharma's high-containment facility will begin distributing the drug in the agreed areas by 2026.
The Series C funding will be channelled towards advancing ArsenalBio’s T cell engineering technology.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
